Special Issue

Pharmacogenomics in Drug Development

Submission Deadline: December 31, 2022 (Open) Submit Now

Guest Editor

Eugenia Yiannakopoulou, MD, MSc, PhD

Academic Teacher, Department of Biomedical Sciences, Faculty of Health Sciences, University of West Attica, Athens, Greece

Website | E-Mail

Research Interests: Pharmacogenomics and drug safety; non steroidal anti-inflammatory agents; prooxidants-antioxidants; systematic review-meta-analysis; breast cancer endocrine treatment; breast cancer targeted therapy; breast cancer chemoprophylaxis

About This Topic

Pharmacogenomics is the study of how genes affect a person’s response to drugs. Its name (pharmaco- + genomics) reflects its combining of pharmacology and genomics. Pharmacogenomics may be applied to several areas of medicine, including pain management, cardiology, oncology, and psychiatry. A place may also exist in forensic pathology, in which pharmacogenomics can be used to determine the cause of death in drug-related deaths where no findings emerge using autopsy. In addition, pharmacogenomics is an important part of precision medicine, as well as one of the most promising parts in the field of precision medicine to realize the clinical routine use of pharmacogenomics and promote the progress of precision medicine.

Pharmacogenomics studies require a multidisciplinary approach because drug targets and adverse effects often involve different organ systems or clinical specialties. They require expertise in many different areas, both preclinical and clinical, including but not limited to pharmacology, genetics, genomics, statistics, bioinformatics, and medicine.

The field of pharmacogenomics is still in its infancy. Its use is currently quite limited, but new approaches are under study in clinical trials. Therefore, in this special issue, we will seek to the articles which reflect the information on current research of pharmacogenomics and drug development. Original research reports, review articles, communications, and perspectives etc. are welcome in all areas pertinent to this topic.

Manuscript Submission Information

Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (genetics@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.

Welcome your submission!

Publication

Open Access Review Immunomodulatory Benefits of Probiotic Bacteria: A Review of Evidence by Samson Adedeji Adejumo  , Angus Nnamdi Oli  , Adekunle Babajide Rowaiye  , Nwamaka Henrietta Igbokwe  , Chinelo Kene Ezejiegu  and Zwanden Sule Yahaya Received: 11 April 2023;  Published: 11 December 2023;  doi: 10.21926/obm.genet.2304206 Abstract Over the past few decades, probiotics have emerged as a viable medical tool for preventing and/or treating diseases. This narrative review provides recent findings on Probiotics and their benefits on the host immune system. It also highlights the specific mechanisms through which probiotics mediate those benefits. The study also explores the [...]

Open Access Review Mycobacterium Tubercular Mediated Inflammation and Lung Carcinogenesis: Connecting Links by Abhay Vashishth  , Mohd Shuaib  , Tanya Bansal  and Shashank Kumar Received: 03 September 2022;  Published: 21 June 2023;  doi: 10.21926/obm.genet.2302183 Abstract Lung cancer is a leading cause of death among all the cancer worldwide and it has the highest occurrence and mortality rates. Mycobacterium tuberculosis (MTB) induced tuberculosis has been known as one of the risk factors for lung carcinogenesis. The exact mechanism of MTB is understood to date. Severa [...]